At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 29, 2026 at 16:05 ET
Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission in induction non-responders and 45.5% recapture of remission in relapsers. The expanded safety database (1,704 patient-years) showed malignancy rates consistent with UC background rates. The company remains on track for NDA submission in Q4 2026.
- 37.2% of induction non-responders achieved clinical remission at Week 44 on 50 mg obefazimod
- 45.5% of patients who relapsed on 25 mg and escalated to 50 mg recaptured clinical remission
- Exposure-adjusted malignancy rates (excluding NMSC) were 0.35 per 100 PY in all-active combined, within UC background range of 0.30–0.70
- NDA submission for obefazimod in UC remains on track for Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access